Date:	$\sqrt{7}$	My 7	she. 15 7	rh, so	1/				
Your Name:				hura	Don				
Manuscript '	Title: Mir	ogabalir	treament	of postope	rative neuro	pathic pain	after thorac	cic surgery: study	
	pro	otocol fo	r a multicen	ter, randon	nized, open-	label, parall	el-group, int	terventional trial	
Manuscript	number (	if knowr	າ):						

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,	Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
1	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
}	No time limit for this item.		
\	1		
Ì			
		Time frame: past	36 months
2	Grants or contracts from	None	
]	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
<u> </u>	100		
4	Consulting fees	_ <mark>✓_</mark> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	<u>✓_</u> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>✓_</u> None
13	Other financial or non- financial interests	None

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article
processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/7/13
Your Name:_Takuro Miyazaki
Manuscript Title: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study
protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
Manuscript number (if known): JTD-21-741

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,	Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ <b></b> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ <u>✓</u> None	
4	Consulting fees	_ <b>✓</b> None	

5	Payment or honoraria for	None	
5	lectures, presentations,	Daiichi Sankyo Co., Ltd	Payments were made to me.
	speakers bureaus,	Danielli Jankyo Co., Ltu	r dyments were made to me.
	manuscript writing or		
	educational events		
6	Payment for expert	<u>✓</u> None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	✓ None	
,	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	4 1	
11	Stock or stock options	None	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>✓</u> None	
	financial interests		

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article processing charges. I have received honoraria for lectures from Daiichi Sankyo Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:	7. 29. 70		
Your Name:	TOMOSHI	TSUCHETA	
Manuscript Title: I	Mirogabalin treatm	ent of postoperative neuro	pathic pain after thoracic surgery: study
-	protocol for a multi	center, randomized, open-l	abel, parallel-group, interventional trial
Manuscript numb	er (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name ail entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present	None	0.38m (0.220 MOS (1.290 MO (4.21 O ) )
	manuscript (e.g., funding, provision of study materials,	Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
į.	medical writing, article processing charges, etc.)	manufacture to the second seco	Treat - Treatment and treatmen
<b>(</b> )	No time limit for this item.	T 12 12 12 12 12 12 12 12 12 12 12 12 12	
1	To time inner or this recin	· · · · · · · · · · · · · · · · · · ·	
ii G	ļ		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
		1/	
4	Consulting fees	None	

_		1	10 Cm
	4	il	08 07 2 181 E W 1922 RG
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	\/_None	
	testimony	2-	
		3.2	
7	Support for attending	None	
	meetings and/or travel		
		11 - 10 - 11 1	
	**	,	<u>u</u>
8	Patents planned, issued or	None	- 1 0 A 0 0 0 0 0 0 A
	pending		west
	_	- 1500 <b>4</b> 0	
9	Participation on a Data	V None	
	Safety Monitoring Board or		
	Advisory Board	. 5.	
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	1	V 100 W = 100
11	Stock or stock options	None	
	= -	/	
12	Receipt of equipment,	None	7
	materials, drugs, medical		2.5 30
	writing, gifts or other		
	services	-6/	
13	Other financial or non-	None	
	financial interests		4.1 4.2

Dailchi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article
processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date:14 July 2021
Your Name:Keitaro Matsumoto
Manuscript Title: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study
protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,	Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame, nest	26 months
2		Time frame: past	36 MONTINS
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	<b>X</b> None	
	meetings and/or travel		
8	Patents planned, issued or	<b>X</b> None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<b>X</b> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
4.5	services		
13	Other financial or non-	XNone	
	financial interests		

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article processing charges.
processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date:_2021.7.13
Your Name:_Koichi Tomoshige
Manuscript Title: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study
protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,	Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_☑_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ <u>✓</u> _None	
4	Consulting fees	<u></u> ✓ None	

		,	
5	Payment or honoraria for	<u>⊿</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	_	
6	Payment for expert	<u>∠</u> None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	<u> </u>	
	pending		
9	Participation on a Data	_ <u>✓</u> _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_☑_None	
	in other board, society, committee or advocacy		
	group, paid or unpaid	_	
11	Stock or stock options	None	
12	Receipt of equipment,	<u>⊿</u> None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ <b>∠</b> None	
	financial interests		
		·	

•

Please place an "X" next to the following statement to indicate your agreement:

Date:	July,15,2021
Your Name:_	Ryusuke Machino
Manuscript 1	itle: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study
	protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
Manuscrint r	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
		Time frame: pas	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None 🗹	
3	Royalties or licenses	None 🗹	
4	Consulting fees	None 🗹	

-		5	
5	Payment or honoraria for	None 🗹	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None 🗹	
	testimony		
	,		
7	Support for attending	None 🗹	
	meetings and/or travel		
	-		
8	Patents planned, issued or	None 🗹	
	pending		
9	Participation on a Data	None 🗹	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None 🗹	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None ☑	
11	Stock of Stock options	None 🗹	
12	Receipt of equipment,	None 🔽	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None 🗹	
	financial interests		

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article processing charges.
processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date:	07/27/2021
<b>Your Nam</b>	ne:Satoshi Mizoguchi
Manuscri	pt Title: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study
	protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
Manuscri	int number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	<u>x</u> None	
4	Consulting fees	x None	

			_ <del>_</del>
5	Payment or honoraria for	x_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x_None	
	testimony		
-		N.	
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	xNone	
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	x None	
	financial interests		
			•

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date: July 15, 2021
Your Name: Takamune Matsumoto
Manuscript Title: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study
protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,		Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 N	
6	Payment for expert	None	
	testimony		
7	Cumport for attending	A News	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	_
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ <b>✓</b> None	
	financial interests		

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date: July 12, 202	ate: Ju	ulv 1	L2, 2	2021
--------------------	---------	-------	-------	------

Your Name: Keita Yamaguchi

Manuscript Title: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study

protocol for a multicenter, randomized, open-label, parallel-group, interventional trial

Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,	Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	x None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x_None	
6	Payment for expert testimony	xNone	
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or pending	x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	xNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x_None	
11	Stock or stock options	x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	xNone	
13	Other financial or non- financial interests	None Daiichi Sankyo Co., Ltd.	Employment

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article
processing charges. I am a current employee of Daiichi Sankyo Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:	<b>09JU</b>	JL2021
-------	-------------	--------

Your Name: Hiroshi Takatsuna

Manuscript Title: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study

protocol for a multicenter, randomized, open-label, parallel-group, interventional trial

Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,	Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	x_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>x</u> None	
4	Consulting fees	x_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x_None	
6	Payment for expert testimony	xNone	
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or pending	x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	xNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x_None	
11	Stock or stock options	x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	xNone	
13	Other financial or non- financial interests	None Daiichi Sankyo Co., Ltd.	Employment

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article
processing charges. I am a current employee of Daiichi Sankyo Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:12J	<b>UL2021</b>
----------	---------------

Your Name: Kazuhito Shiosakai

Manuscript Title: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study

protocol for a multicenter, randomized, open-label, parallel-group, interventional trial

Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials, medical writing, article	Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the medical writing support and the article processing charges.
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	26 months
2	Grants or contracts from	x_None	30 months
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	x_None	
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or pending	x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x_None	
11	Stock or stock options	x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x_None	
13	Other financial or non- financial interests	None Daiichi Sankyo Co., Ltd.	Employment

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article
processing charges. I am a current employee of Daiichi Sankyo Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021/7/13
Your Name:TAKESHI NAGAYASU
Manuscript Title: Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study
protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
Manuscript number (if known): JTD-21-741

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding,	None Daiichi Sankyo Co., Ltd.	Funded the research reflected in this manuscript, the
	provision of study materials,	Daliciii Salikyo Co., Etu.	medical writing support and the article processing charges.
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	_×_None	
	in item #1 above).		
3	Royalties or licenses	×None	
4	Consulting fees	× None	

		1	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Daiichi Sankyo Co., Ltd	Payments were made to me.
6	Payment for expert testimony	×None	
	cesumony		
7	Support for attending meetings and/or travel	_×None	
8	Patents planned, issued or pending	_×None	
	pending		
9	Participation on a Data	_×None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	_xNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_×None	
12	Receipt of equipment,	×None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_xNone	
	financial interests		

Daiichi Sankyo Co., Ltd. funded the research reflected in this manuscript, the medical writing support and the article processing charges. I have received honoraria for lectures from Daiichi Sankyo Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement: